Persistent Bone Marrow Minimal Residual Disease is a Poor Prognostic Marker for Neuroblastoma

被引：0
|
作者：
Feng, C. [1 ]
Li, Y. [1 ]
Wu, P. [1 ]
Xiong, X. [1 ]
Peng, X. [1 ]
Weng, W. [1 ]
机构：
[1] Sun Yat Sen Mem Hosp, Pediat Hematol Oncol, Guangzhou, Guangdong, Peoples R China
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO130 SIOP
引用
收藏
页码：S605 / S606
页数：2
相关论文
共 50 条
  • [41] NONHOMOGENEOUS DISTRIBUTION OF LEUKEMIA IN THE BONE-MARROW DURING MINIMAL RESIDUAL DISEASE
    MARTENS, ACM
    SCHULTZ, FW
    HAGENBEEK, A
    BLOOD, 1987, 70 (04) : 1073 - 1078
  • [42] Detection of Minimal Residual Disease in Blood and Bone Marrow in Early Breast Cancer
    Krishnamurthy, S.
    Singh, B.
    Reuben, J.
    Lodhi, A.
    Cristofanilh, M.
    Lucci, A.
    MODERN PATHOLOGY, 2009, 22 : 51A - 52A
  • [43] Detection of Minimal Residual Disease in Blood and Bone Marrow in Early Breast Cancer
    Krishnamurthy, S.
    Singh, B.
    Reuben, J.
    Lodhi, A.
    Cristofanilli, M.
    Lucci, A.
    LABORATORY INVESTIGATION, 2009, 89 : 51A - 52A
  • [44] MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA: A BONE MARROW TRANSPLANTATION CENTER EXPERIENCE
    Ikoma, Maura
    Penitenti, Marcimara
    Marques, Camila
    Mattos, Ederson
    Colturato, Vergilio
    Souza, Mair
    Mauad, Marcos
    Pedro, Andrea
    Cantarelli, Andiara
    Pascolat, Fabricio
    Dameto, Ana
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2011, 80B (06) : 416 - 417
  • [45] MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CML FOLLOWING BONE-MARROW ALLOGRAFTING
    XU, WM
    PIAO, XH
    ADDY, PL
    JAMAL, N
    MINDEN, M
    MESSNER, H
    EXPERIMENTAL HEMATOLOGY, 1993, 21 (08) : 1128 - 1128
  • [46] Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients
    Yamamoto, Nobuyuki
    Kozaki, Aiko
    Hartomo, Tri Budi
    Yanai, Tomoko
    Hasegawa, Daiichiro
    Kawasaki, Keiichiro
    Kosaka, Yoshiyuki
    Matsuo, Masafumi
    Hirase, Satoshi
    Mori, Takeshi
    Hayakawa, Akira
    Iijima, Kazumoto
    Nishio, Hisahide
    Nishimura, Noriyuki
    ONCOLOGY LETTERS, 2015, 10 (05) : 3228 - 3232
  • [47] Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood
    San Lin, Kyaw
    Uemura, Suguru
    Thwin, Khin Kyae Mon
    Nakatani, Naoko
    Ishida, Toshiaki
    Yamamoto, Nobuyuki
    Tamura, Akihiro
    Saito, Atsuro
    Mori, Takeshi
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    Nino, Nanako
    Nagano, China
    Takafuji, Satoru
    Iijima, Kazumoto
    Nishimura, Noriyuki
    TRANSLATIONAL ONCOLOGY, 2021, 14 (08):
  • [48] Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
    van Wezel, Esther M.
    van Zogchel, Lieke M. J.
    van Wijk, Jalenka
    Timmerman, Ilse
    Vo, Ngoc-Kim
    Zappeij-Kannegieter, Lily
    DeCarolis, Boris
    Simon, Thorsten
    van Noesel, Max M.
    Molenaar, Jan J.
    van Groningen, Tim
    Versteeg, Rogier
    Caron, Huib N.
    van der Schoot, C. Ellen
    Koster, Jan
    van Nes, Johan
    Tytgat, Godelieve A. M.
    JCO PRECISION ONCOLOGY, 2019, 3
  • [49] Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
    Matthay, KK
    Reynolds, CP
    BRITISH JOURNAL OF CANCER, 2000, 83 (09) : 1121 - 1123
  • [50] The Effects of Rosiglitazone on Minimal Residual Disease Model of Neuroblastoma
    Altun, Z.
    Ayla, M.
    Aktas, S.
    Pamukoglu, A.
    Ercetin, P.
    Olgun, N.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S223 - S223
12345